Related Experiment Video
Updated: May 10, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor
Antonio Eduardo P Pesaro1, Carlos V Serrano, Marcelo Katz
1Hospital Israelita Albert Einstein, Av Albert Einstein, Paulo-SP, Brazil. antonioepp@einstein.br
Insights
Intensifying lipid-lowering therapy in coronary artery disease patients with simvastatin or ezetimibe did not improve endothelial progenitor cells (EPCs). Both strategies equally reduced LDL cholesterol but did not impact EPC levels or function.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Biology
Background:
- Coronary artery disease (CAD) management requires statin therapy to achieve low cholesterol levels and reduce cardiovascular events.
- Many CAD patients on moderate statin doses fail to reach target cholesterol levels.
- The impact of intensified lipid-lowering strategies on endothelial progenitor cells (EPCs), indicators of endothelial function, remains unclear.
Purpose of the Study:
- To compare the effects of increasing simvastatin dosage versus adding ezetimibe on EPC levels in stable CAD patients with elevated LDL cholesterol.
- To assess if enhanced lipid-lowering strategies offer additional benefits beyond cholesterol reduction for endothelial health.
Main Methods:
- A randomized trial involving 68 stable CAD patients on simvastatin 20 mg with LDL-C >70 mg/dL.
- Participants were assigned to receive either ezetimibe 10 mg/simvastatin 20 mg or simvastatin 80 mg for 6 weeks.
- Circulating EPCs were quantified using flow cytometry before and after treatment.
Main Results:
- Both treatment strategies yielded comparable reductions in LDL cholesterol levels.
- Neither increasing simvastatin to 80 mg nor adding ezetimibe significantly altered circulating EPC levels.
- No significant differences in treatment effects on EPCs were observed between the two groups.
Conclusions:
- Intensifying lipid-lowering therapy with high-dose simvastatin or adding ezetimibe provides similar cholesterol reduction in CAD patients.
- These intensified strategies do not demonstrate incremental benefits on circulating EPC levels compared to moderate-dose statin therapy.
- The pleiotropic effects of statins on EPCs are not enhanced by more aggressive lipid-lowering approaches.
Background:
Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether therapeutic uptitration with different lipid-lowering strategies has a similar "pleiotropic" effect on atherosclerotic endothelial dysfunction evaluated by measurement of endothelial progenitor cells (EPCs).
Objective:
We sought to compare, in patients with stable CAD and with a low-density lipoprotein cholesterol (LDL-C) >70 mg/dL on treatment with simvastatin 20 mg, the effects on EPCs by increasing simvastatin to 80 mg versus adding ezetimibe 10 mg.
Methods:
Patients (n = 68, 63 ± 9 years, 39% men) were randomly allocated to receive ezetimibe 10/simvastatin 20 mg or simvastatin 80 mg for 6 weeks. Circulating EPCs were measured by flow cytometry before and after the treatment.
Results:
Both strategies presented similar effects on metabolic parameters. The LDLs were equally reduced by ezetimibe 10/simvastatin 20 mg and simvastatin 80 mg (28.9% ± 13% vs 21.1% ± 33%; P = .46, respectively). The levels of EPCs were unaffected by ezetimibe 10/simvastatin 20 mg (median [25th, 75th]: pre- vs posttreatment, 7.0 [2.3; 13.3] vs 3.1 [0.1; 13.2] EPCs/10(4) mononuclear cells; P = .43) or simvastatin 80 mg (pre- vs posttreatment, 6.1 [2.9; 15.2] vs 4.0 [1.4; 10.7] EPCs/10(4) mononuclear cells; P = .5), and there were no differences between the groups on treatment effects (P = .9).
Conclusions:
Among stable patients with CAD and with an LDL-C >70 mg/dL on simvastatin 20 mg, increasing simvastatin dose to 80 mg or adding ezetimibe 10 mg promoted similar further cholesterol reduction but did not have incremental effects on circulating EPCs. These data suggest that the effects of simvastatin moderate doses on EPCs are not increased by intensive lipid-lowering strategies (clinicaltrials.gov: NCT00474123).
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment